Anti-Human CD70 Antibody (1F6)

Catalog No.

FHE01920

Species reactivity

Human

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Conjugation

Unconjugated

Target

CD27 ligand, CD70, TNFSF7, CD27LG, CD27L, CD70 antigen, Tumor necrosis factor ligand superfamily member 7, CD27-L

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P32970

Applications

FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

1F6

Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma., PMID:40518621

Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study., PMID:40404633

The CD70-CD27 axis in cancer immunotherapy: Predictive biomarker and therapeutic target., PMID:40388162

CD70-Targeted [18F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal Carcinoma: A Proof-of-Concept Study., PMID:40306966

CD70-targeted cancer theranostics: Progress and challenges., PMID:40250430

CD70 recruitment to the immunological synapse is dependent on CD20 in B cells., PMID:40232798

Single-cell RNA-sequencing reveals cellular heterogeneity and immune microenvironment characteristics between ocular adnexal mucosa-associated lymphoid lymphoma and IgG4-related ophthalmic disease., PMID:40078987

CD8α and CD70 mark human natural killer cell populations which differ in cytotoxicity., PMID:40046047

Development and Preclinical Evaluation of [64Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics., PMID:40015924

A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells., PMID:39906740

Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes., PMID:39867912

Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies., PMID:39864030

Direct Inhibitory Effect of HTLV-1-Infected T Cells on the Production of Anti-Ro/SS-A Antibody by B Cells from Patients with Sjögren's Syndrome., PMID:39775490

A mechanistic, functional, and clinical perspective on targeting CD70 in cancer., PMID:39725151

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML., PMID:39571145

CD70: An Emerging Anticancer Target in Renal Cell Carcinoma and Beyond., PMID:39570653

CD70-Targeted Immuno-PET/CT Imaging of Clear Cell Renal Cell Carcinoma: A Translational Study., PMID:39510586

Development of bioassay platforms for biopharmaceuticals using Jurkat-CAR cells by AICD., PMID:39197208

Expression of Potential Antibody-Drug Conjugate Targets in Cervical Cancer., PMID:38730739

Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models., PMID:38646638

The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment., PMID:38637886

CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma., PMID:38583184

ImmunoPET/CT imaging of clear cell renal cell carcinoma with [18F]RCCB6: a first-in-human study., PMID:38480552

Benzoic acid, 4-hydroxy-, methyl ester from Smilax zeylanica Linn emerges as a potent inhibitor of CD27/CD70 signaling pathway., PMID:38353477

Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas., PMID:37998391

Fcγ receptor binding is required for maximal immunostimulation by CD70-Fc., PMID:37965342

Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study., PMID:37914483

The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling., PMID:37849799

PAX5 and CD70 are expressed in thymic carcinoma but not in atypical thymoma (WHO type B3 thymoma): an immunohistochemical analysis of 60 cases., PMID:37696593

METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer., PMID:37648786

Fundamental Characterization of Antibody Fusion-Single-Chain TNF Recombinant Proteins Directed against Costimulatory TNF Receptors Expressed by T-Lymphocytes., PMID:37371066

Generation of a CD70-Specific Fusion Nanobody with IgG Recruiting Capacity for Tumor Killing., PMID:37361386

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment., PMID:37345056

Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models., PMID:37093350

Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer., PMID:36970072

Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia., PMID:36932256

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance., PMID:36787696

Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy., PMID:36779592

Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities., PMID:36745503

CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19., PMID:36537906

Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment., PMID:36394119

Identification and characterization of blocking nanobodies against human CD70., PMID:36239354

Adenoviral delivery of soluble ovine OX40L or CD70 costimulatory molecules improves adaptive immune responses to a model antigen in sheep., PMID:36211974

When to suspect inborn errors of immunity in Epstein-Barr virus-related lymphoproliferative disorders., PMID:36209991

Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy., PMID:36100308

Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2+ breast cancer by ceramide-loaded nanoparticles., PMID:36095190

CD4+CD8+ T follicular helper cells regulate humoral immunity in chronic inflammatory lesions., PMID:36091071

A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma., PMID:36055572

New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes., PMID:35886899

Agonistic anti-CD27 antibody ameliorates EAE by suppressing IL-17 production., PMID:35856659

Document Download

Anti-Human CD70 Antibody (1F6).pdf